Clinical trials in Villejuif – page 206

3 340 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Villejuif at a glance

3 340

clinical trials

Research sites2

Quick filters

3 340 trials in Villejuif

Open in trial search

Non-small cell lung cancer

Not recruiting

Study of Amivantamab with Carboplatin and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

Registered drugNo placebo

Study of Amivantamab with Carboplatin and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:Janssen Cilag International

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational

France

Participants:18–64 years · 65+ years
Substances:Xevinapant
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Non-small cell lung cancer stage IV+2

Not recruiting

Study comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer

Registered drugNo placebo

Study comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Brigatinib
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Gastric cancer+7

Not recruiting

Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo

Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Bristol Myers Squibb International Corporation

Contact Research Centre

Hormone receptor positive breast cancer

Not recruiting

Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

Registered drugNo placebo

Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

Registered drugNo placebo

France

Participants:65+ years
Substances:Anastrozole
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Anal squamous cell carcinoma+4

Not recruiting

Study of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas

Registered drugNo placebo

Study of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Unicancer

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study on Talquetamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study on Talquetamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Talquetamab
Sponsor:Janssen Cilag International

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug

Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Atypical haemolytic uraemic syndrome

Not recruiting

Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo

Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo

France

Participants:0–17 years
Substances:Crovalimab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Breast cancer

Not recruiting

Study on the Safety and Effectiveness of Vepdegestrant and Samuraciclib for Adults with ER+ Advanced or Metastatic Breast Cancer

InvestigationalNo placebo

Study on the Safety and Effectiveness of Vepdegestrant and Samuraciclib for Adults with ER+ Advanced or Metastatic Breast Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Samuraciclib
Sponsor:Pfizer Inc.

Contact Research Centre

Endometrial cancer

Not recruiting

Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo

Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency

Not recruiting

Long-term Safety Study of KVD900 for Treating Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema Type I or II

InvestigationalNo placebo

Long-term Safety Study of KVD900 for Treating Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema Type I or II

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Sebetralstat
Sponsor:Kalvista Pharmaceuticals Limited

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

NBTXR3 with radiotherapy
EGFR-ADC therapy combinations
HPV-positive oropharyngeal cancer

02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

Anti-CEACAM5 ADC therapy
Sotorasib combinations
Novel gastrointestinal cancer treatments

03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

Elranatamab-lenalidomide therapy
Belantamab mafodotin combinations
T-cell lymphoma treatments

04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

Novel antibody-drug conjugates
Microbiome-based approaches
Targeted therapy combinations

05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

PARG inhibitor studies
Targeted molecular therapies
Immunotherapy combinations

Back to France All countries